Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Convergence of eicosanoid and integrin biology: 12-lipoxygenase seeks a partner.

Tang K, Cai Y, Joshi S, Tovar E, Tucker SC, Maddipati KR, Crissman JD, Repaskey WT, Honn KV.

Mol Cancer. 2015 Jun 3;14:111. doi: 10.1186/s12943-015-0382-5.

2.

Platelets and cancer: a casual or causal relationship: revisited.

Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV.

Cancer Metastasis Rev. 2014 Mar;33(1):231-69. doi: 10.1007/s10555-014-9498-0. Review.

3.

Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.

Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP Jr.

Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):861-8.

4.

Recommendations for the reporting of specimens containing oral cavity and oropharynx neoplasms. Association of Directors of Anatomic and Surgical Pathology.

Zarbo RJ, Barnes L, Crissman JD, Gnepp DR, Mills SE.

Hum Pathol. 2000 Oct;31(10):1191-3. No abstract available.

PMID:
11203319
5.

The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study.

deVere White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA Jr, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED.

Eur Urol. 2000 May;37(5):595-600.

PMID:
10765099
6.

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.

J Urol. 2000 Apr;163(4):1124-9.

PMID:
10737480
7.

A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies.

Li L, Zhu Z, Joshi B, Zhang C, Johnson CR, Marnett LJ, Honn KV, Crissman JD, Porter AT, Tang DG.

Anticancer Res. 1999 Jan-Feb;19(1A):61-9.

PMID:
10226525
8.

Histopathologic and flow-cytometric analysis of neoplastic and benign "background" tissue in breast carcinoma resections.

Visscher DW, Gingrich DS, Leon-Armin C, Tabaczka P, Crissman JD.

Anal Cell Pathol. 1998;17(3):167-75.

9.

Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.

Bianco FJ Jr, Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, Fridman R, Wood DP Jr.

Clin Cancer Res. 1998 Dec;4(12):3011-6.

10.

BMD188, A novel hydroxamic acid compound, demonstrates potent anti-prostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases.

Tang DG, Li L, Zhu Z, Joshi B, Johnson CR, Marnett LJ, Honn KV, Crissman JD, Krajewski S, Reed JC, Timar J, Porter AT.

Pathol Oncol Res. 1998;4(3):179-90.

11.

Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus.

Joshi US, Dergham ST, Chen YQ, Dugan MC, Crissman JD, Vaitkevicius VK, Sarkar FH.

Pancreas. 1998 Mar;16(2):107-13.

PMID:
9510131
12.

The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma.

Dergham ST, Dugan MC, Joshi US, Chen YC, Du W, Smith DW, Arlauskas P, Crissman JD, Vaitkevicius VK, Sarkar FH.

Cancer. 1997 Aug 1;80(3):372-81.

PMID:
9241070
13.

Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.

Dergham ST, Dugan MC, Arlauskas P, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH.

Int J Pancreatol. 1997 Jun;21(3):225-34.

PMID:
9322121
14.

Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.

Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK, Crissman JD, Sarkar FH.

Int J Pancreatol. 1997 Apr;21(2):127-43.

PMID:
9209954
15.

HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival.

Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH.

Pancreas. 1997 Apr;14(3):229-36.

PMID:
9094152
16.

Molecular genetic analysis in the pathologic evaluation of solid tumors: theory and practice.

Visscher DW, Sarkar FH, Crissman JD.

J Clin Lab Anal. 1997;11(1):10-6. Review. No abstract available.

PMID:
9021519
17.

Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics.

Visscher DW, Wallis T, Awussah S, Mohamed A, Crissman JD.

Genes Chromosomes Cancer. 1997 Jan;18(1):1-7.

PMID:
8993975
18.

Cell cycle analysis of normal, atrophic, and hyperplastic breast epithelium using two-color multiparametric flow cytometry.

Visscher DW, Gingrich DS, Buckley J, Tabaczka P, Crissman JD.

Anal Cell Pathol. 1996 Nov;12(2):115-24.

PMID:
8986295
19.

Tumor suppressor p53 gene mutation in squamous cell carcinoma of the larynx.

Sarkar FH, Sakr WA, Li YW, Jacobs J, Crissman JD.

Diagn Mol Pathol. 1996 Sep;5(3):201-5.

PMID:
8866234
20.

Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma.

Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD.

Diagn Mol Pathol. 1996 Sep;5(3):187-93.

PMID:
8866232
21.

Recommendations for the reporting of urinary bladder specimens that contain bladder neoplasms.

Murphy WM, Crissman JD, Johansson SL, Ayala AG.

Mod Pathol. 1996 Jul;9(7):796-8. No abstract available.

PMID:
8832565
22.

Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations.

Honn KV, Aref A, Chen YQ, Cher ML, Crissman JD, Forman JD, Gao X, Grignon D, Hussain M, Porter AT, Pontes JE, Powell I, Redman B, Sakr W, Severson R, Tang DG, Wood DP.

Pathol Oncol Res. 1996 Mar;2(1-2):98-109.

23.
24.

Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study.

Devere White RW, Deitch AD, Tesluk H, Blumensteinj B, Lowe BA, Sagalowsky AI, Smith JA Jr, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED.

Urol Oncol. 1996 Jan-Feb;2(1):27-34.

PMID:
21224132
25.

Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment.

Honn KV, Aref A, Chen YQ, Cher ML, Crissman JD, Forman JD, Gao X, Grignon D, Hussain M, Porter AT, Pontes JE, Powell I I, Redman B, Sakr W, Severson R, Tang DG, Wood DP Jr.

Pathol Oncol Res. 1996;2(4):276-292.

26.

Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Honn KV, Aref A, Chen YQ, Cher ML, Crissman JD, Forman JD, Gao X, Grignon D, Hussain M, Porter AT, Pontes EJ, Powell I I, Redman B, Sakr W, Severson R, Tang DG, Wood DP Jr.

Pathol Oncol Res. 1996;2(3):191-211.

27.

Age and racial distribution of prostatic intraepithelial neoplasia.

Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD.

Eur Urol. 1996;30(2):138-44. Review.

PMID:
8875194
28.

Clinicopathologic analysis of macrophage infiltrates in breast carcinoma.

Visscher DW, Tabaczka P, Long D, Crissman JD.

Pathol Res Pract. 1995 Nov;191(11):1133-9.

PMID:
8822115
29.

Epidemiology of high grade prostatic intraepithelial neoplasia.

Sakr WA, Grignon DJ, Haas GP, Schomer KL, Heilbrun LK, Cassin BJ, Powell J, Montie JA, Pontes JE, Crissman JD.

Pathol Res Pract. 1995 Sep;191(9):838-41.

PMID:
8606862
30.

Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma.

Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD.

Mod Pathol. 1995 Aug;8(6):665-70.

PMID:
8532703
31.

Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer.

Gao X, Grignon DJ, Chbihi T, Zacharek A, Chen YQ, Sakr W, Porter AT, Crissman JD, Pontes JE, Powell IJ, et al.

Urology. 1995 Aug;46(2):227-37.

PMID:
7624992
32.

Assessment and significance of diploid-range epithelial populations in DNA aneuploid breast carcinomas using multi-parametric flow cytometry.

Visscher DW, Sochacki P, Ottosen S, Wykes S, Crissman JD.

Anal Cell Pathol. 1995 Jun;8(4):267-77.

PMID:
7577742
33.

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith JA Jr, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Barton Grossman H.

Urol Oncol. 1995 May-Jun;1(3):119-26.

PMID:
21224104
34.

Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence.

Visscher DW, Höyhtyä M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R.

Int J Cancer. 1994 Nov 1;59(3):339-44.

PMID:
7927938
35.

Allelic loss in locally metastatic, multisampled prostate cancer.

Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, Crissman JD.

Cancer Res. 1994 Jun 15;54(12):3273-7.

36.

High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases.

Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP.

In Vivo. 1994 May-Jun;8(3):439-43.

PMID:
7803731
37.

c-erbB-2 promoter-specific DNA-binding protein isolated from human breast cancer tissues displays mitogenic activity.

Sarkar FH, Smith MR, Hoover T, Princler G, Crissman JD, Visscher DW, Longo DL, Kung HF, Raziuddin.

J Biol Chem. 1994 Apr 22;269(16):12285-9.

38.

Interaction of transforming growth factor-alpha and epidermal growth factor receptor in breast carcinoma. An immunohistologic study.

Castellani R, Visscher DW, Wykes S, Sarkar FH, Crissman JD.

Cancer. 1994 Jan 15;73(2):344-9.

PMID:
8293398
39.

Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia.

Visscher DW, Sloane BF, Sameni M, Babiarz JW, Jacobson J, Crissman JD.

Mod Pathol. 1994 Jan;7(1):76-81.

PMID:
8159656
40.

Dissociation of intact cells from tumors and normal tissues.

Visscher DW, Crissman JD.

Methods Cell Biol. 1994;41:1-13. Review. No abstract available.

PMID:
7861961
41.

Flow cytometric enumeration and kinetic analysis of inflammatory cell populations in breast carcinomas.

Visscher DW, VanBree G, Ottosen S, Wykes S, Crissman JD.

Anal Cell Pathol. 1993 Nov;5(6):321-30.

PMID:
8305328
42.

Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene.

Sarkar FH, Ball DE, Li YW, Crissman JD.

DNA Cell Biol. 1993 Sep;12(7):611-5.

PMID:
8104414
43.

Quantitative analysis of Her-2/neu (ERBB2) gene expression using reverse transcriptase polymerase chain reaction.

Sarkar FH, Visscher DW, Crissman JD.

Diagn Mol Pathol. 1993 Sep;2(3):210-8.

PMID:
7506983
44.

The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients.

Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD.

J Urol. 1993 Aug;150(2 Pt 1):379-85.

PMID:
8326560
45.

A method for PCR sequencing of the p53 gene from a single 10-microns frozen or paraffin-embedded tissue section.

Sarkar FH, Li YW, Crissman JD.

Biotechniques. 1993 Jul;15(1):36-8. No abstract available.

PMID:
8363836
46.

Image cytophotometric DNA histogram heterogeneity in adenocarcinoma of the breast.

Visscher DW, Shaheen C, Drozdowicz S, Crissman JD.

Anal Quant Cytol Histol. 1993 Jun;15(3):206-12.

PMID:
8347261
47.

Comparison of DNA content in primary and lymph node metastases in prostate adenocarcinoma.

Babiarz J, Peters JM, Miles B, Crissman JD.

Anal Quant Cytol Histol. 1993 Jun;15(3):158-64.

PMID:
8347255
48.

Immunohistologic evaluation of invasion-associated proteases in breast carcinoma.

Visscher DW, Sarkar F, LoRusso P, Sakr W, Ottosen S, Wykes S, Crissman JD.

Mod Pathol. 1993 May;6(3):302-6.

PMID:
8346178
49.

DNA quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate.

Crissman JD, Sakr WA, Hussein ME, Pontes JE.

Prostate. 1993;22(2):155-62.

PMID:
8456053
50.

Premalignant lesions of the upper aerodigestive tract: biomarkers of genetic alterations, proliferation, and differentiation.

Crissman JD, Visscher DW, Sarkar FH.

J Cell Biochem Suppl. 1993;17F:192-8. Review.

PMID:
8412193

Supplemental Content

Loading ...
Support Center